# Preprocedural computed tomography angiography-guided transcatheter arterial embolization for managing esophageal cancer bleeding: a case series study

## TL;DR

This study shows that CTA-guided TAE is effective for stopping bleeding in esophageal cancer patients, with high success rates and manageable side effects.

## Contribution

The study introduces preprocedural CTA guidance as a novel approach to improve TAE outcomes for esophageal cancer bleeding.

## Key findings

- Seven out of eight patients achieved both technical and clinical success with CTA-guided TAE.
- Five patients experienced recurrent bleeding, with four dying and one successfully treated with a second TAE.
- CTA-guided TAE was associated with mild and manageable complications in most patients.

## Abstract

While endoscopy is the first-line treatment for non-variceal upper gastrointestinal hemorrhage, its role in managing upper gastrointestinal tumor bleeding is limited. This study aims to evaluate the effect of computed tomography angiography (CTA)-guided transcatheter arterial embolization (TAE) in achieving hemostasis for esophageal cancer bleeding.

A retrospective case series was conducted at our hospital, involving eight patients who underwent preprocedural CTA-guided TAE for esophageal cancer bleeding between August 2023 and August 2024.

Of the eight patients (seven males, mean age 67 ± 12.9 years) who underwent CTA-guided TAE for esophageal cancer bleeding, seven achieved both technical and clinical success. One patient failed to achieve embolization due to missed identification of a pseudoaneurysm in the superior thyroid artery, resulting in death from hemorrhage. Two patients experienced mild chest or neck discomfort, which resolved with conservative management. During follow-up, five patients experienced recurrent hemorrhage, with four dying and one successfully treated with a second TAE. One of the remaining two patients died from disease progression, and the other remained recurrence-free for 270 days.

CTA-guided TAE demonstrates high technical and clinical success rates for achieving hemostasis in esophageal cancer bleeding with mild and manageable complications.